SecBot SecBot
PRESS-RELEASE ·Filed Nov 5, 2026

PMN

ProMIS Neurosciences Inc.
NEUTRAL
Impact 2/10
Horizondays Processed11d 19h ago WireGlobeNewswire
Press release · Announcement
Actionable Insight • Neutral

Monitor the conference presentations and any subsequent press releases for updates on PMN310's Phase 1b data or pipeline progress; this announcement alone provides no new information to change the investment thesis.

DirectionNeutral
Confidencehigh
Horizondays

Drug in focus

PMN drug pipeline →

PMN310

▲ Bullish Named in this press release
Impact
Phase
Phase 1b
Time to market
Years away — Phase 1b enrollment complete, but Phase 2/3 trials, if initiated, would take multiple years. Best-case earliest approval likely 2029+.
Next catalyst
None dated

What to watchThe Phase 1b PRECISE-AD interim analysis (blinded 6-month biomarker data) is the critical near-term catalyst, expected within weeks. Positive biomarker signals (Aβ oligomer reduction, pTau) could send the stock sharply higher given the low float and ~$12.80 share price vs. ~$32 mean analyst target. However, a Phase 1b readout is not de-risking enough to guarantee Phase 2/3 success, and the competitive Alzheimer's landscape is crowded with approved drugs (lecanemab, donanemab).

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$3.65
T+0 close · Nov 5, 2026 · via day close
Latest settled
−4.66%
T+5 · $3.48
Vs SPY
−7.95%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $3.65entry
  2. T+1 · 11d ago +13.97%α +13.66% · $4.16
  3. T+5 · 5d ago −4.66%α −7.95% · $3.48
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ProMIS Neurosciences issued a press release announcing its participation in six investor and medical conferences in November and December 2026, including fireside chats and a poster presentation of previously disclosed interim safety and biomarker data from its PRECISE-AD study. The release contains no new financial data, clinical results, or material corporate developments.

Key Facts

  • ProMIS will present at Guggenheim, Stifel, UBS, Jefferies, CTAD, and Evercore conferences from Nov 9 to Dec 2, 2026.
  • The CTAD poster (P047) covers interim safety and biomarker data from the PRECISE-AD study, previously presented on July 28, 2026.
  • No new clinical data, financial results, or business developments were disclosed.

Financial Impact

No financial impact disclosed; routine conference participation with no material news.

Risk Factors

  • No new clinical or financial data released; the filing is a routine investor relations update.
  • Market cap is small ($27M) and stock is highly volatile (23.2% normal daily move), so even minor news can cause outsized moves.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
91% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3396211

Track record

16 reports on PMN

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +43.16% at T+60 after the Mar 18, 2026 report. 4 of 5 went positive at some point.

Filters
  1. Nov 17, 2026today Press Release Neutral 3/10 Entry price pending
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $3.25 Now $3.31 +1.85% settles Nov 18
  3. Nov 12, 20264d ago 8-K Neutral 4/10 Entry $3.29 to $3.31 Now $3.31 +0.61% ▲ +0.61% +2.52% vs SPY
  4. Nov 12, 20264d ago SC 13G Neutral 4/10 Entry $3.48 to $3.29 Now $3.31 −4.89% ▼ −5.46% −5.10% vs SPY
  5. Nov 12, 20264d ago 8-K Neutral 5/10 Entry $3.48 to $3.29 Now $3.31 −4.89% ▼ −5.46% −5.10% vs SPY
  6. Nov 6, 202610d ago Insider Cluster Bullish 4/10 Entry $4.16 to $4.05 Now $3.31 −20.43% ▼ −2.64% −5.01% vs SPY
  7. Nov 5, 202611d ago Press Release Neutral 2/10 Viewing Entry $3.65 to $4.16 Now $3.31 −9.32% ▲ +13.97% +13.66% vs SPY
  8. Oct 6, 20265w ago 3 Neutral 2/10 Entry $9.12 to $9.15 Now $3.31 −63.71% ▲ +0.33% +0.75% vs SPY
  9. Oct 6, 20265w ago Press Release Neutral 3/10 Entry $9.21 to $9.12 Now $3.31 −64.06% ▼ −0.98% −0.74% vs SPY
  10. Sep 1, 202610w ago Press Release Neutral 3/10 Entry $13.35 to $13.98 Now $3.31 −75.21% ▲ +4.68% +4.24% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026